Clinical Impact of New HIV Data From EACS 2021*

Dr Babafemi Taiwo, MBBS, recaps key studies on HIV drug resistance from EACS 2021.

Babafemi Taiwo, MBBS Released: November 23, 2021

Here’s how the IMEA 055 FAST study of BIC/FTC/TAF in a test-and-treat model fits with our approach at Ward 86.

Monica Gandhi, MD, MPH Released: December 1, 2021

Listen to expert insights from Tristan J. Barber, MA, MD, FRCP, on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.

Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

Read expert faculty members’ summaries of key studies from EACS 2021, including results from studies on BIC/FTC/TAF in a test-and-treat model; islatravir and doravirine in treatment naïve patients; DTG/3TC in patients with an M184V mutation; long-acting CAB + RPV by BMI category, patient satisfaction, and outcomes after discontinuation; lenacapavir in heavily treatment experienced patients; and COVID-19 vaccine effectiveness and the impact of the pandemic on virologic suppression in PWH.

Tristan J. Barber, MA, MD, FRCP Chloe Orkin, MBChB, FRCP, MD Jürgen K. Rockstroh, MD Released: November 15, 2021

Hear from CCO’s expert faculty, Dr. Chloe Orkin, as she presents her insights on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations, and more.

Chloe Orkin, MBChB, FRCP, MD Released: November 17, 2021

Hear from expert faculty as he presents his unique insights on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.

Jürgen K. Rockstroh, MD Released: November 19, 2021

Hear from expert faculty as he presents his unique insights on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.

Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Join the conversation about challenges in linking people with HIV to care in your location.

Milosz Parczewski, MD, PhD Released: December 3, 2021

Here’s why I’m concerned by data on rates of virologic suppression in Europe.

Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Here’s why we should be loudly and publicly promoting PrEP as a healthy choice for all those at risk for HIV.

Darrell H. S. Tan, MD, FRCPC, PhD Released: November 19, 2021

Use of long-acting antiretroviral therapy represents a quantum shift in HIV management due to its potent, sustainable effects.

Don Smith, MD Released: November 23, 2021

My thoughts on the implications of the IMEA 055 FAST study data presented at EACS 2021 for linkage to care among PWH in Latin America.

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

New data from EACS 2021 highlight the unique challenges of older people living with HIV, particularly those living in the Asia-Pacific region.

Yan Zhao, MD Released: November 30, 2021

Undiagnosed HIV infection increases late diagnosis of HIV/AIDS and delays ART initiation, increasing HIV-related morbidity and mortality and risk for HIV transmission. Here are my thoughts on how we can close the gap on missed opportunities for HIV testing in Africa and around the globe.

Nelly Mugo, MBChB, MMed, MPH Released: December 22, 2021

Leitura dos resumos dos membros do corpo docente especialistas dos principais estudos da conferência EACS 2021, incluindo resultados de estudos sobre BIC/FTC/TAF num modelo de teste e tratamento; islatravir e doravirina em pacientes sem tratamento prévio; DTG/3TC em pacientes com uma mutação M184V; CAB + RPV de longa duração por categoria de IMC, satisfação do paciente e resultados após a descontinuação; lenacapavir em pacientes com bastante experiência de tratamento; e eficácia da vacina COVID-19 e o impacto da pandemia na supressão virológica em pessoas com VIH (PWH).

Tristan J. Barber, MA, MD, FRCP Chloe Orkin, MBChB, FRCP, MD Jürgen K. Rockstroh, MD Released: December 14, 2021

Podrá leer resúmenes de miembros expertos del panel sobre los estudios principales de EACS 2021, incluidos los resultados sobre BIC/FTC/TAF en un modelo de análisis y tratamiento; islatravir y doravirina en el tratamiento de pacientes que no han recibido tratamiento previo; DTG/3TC en pacientes con una mutación M184V; CAB + RPV de larga duración por categoría de IMC, satisfacción del paciente y resultados tras la interrupción; lenacapavir en pacientes muy tratados; y efectividad de la vacuna contra la COVID-19 y el impacto de la pandemia en la supresión virológica de las personas con VIH.

Tristan J. Barber, MA, MD, FRCP Chloe Orkin, MBChB, FRCP, MD Jürgen K. Rockstroh, MD Released: December 17, 2021